Brazil moves to standardise device nomenclature and labelling
This article was originally published in Clinica
Brazil is considering using a translation of the Global Medical Device Nomenclature (GMDN) as the basis of its "common denomination of healthcare products" (DCB-PS). The plans are subject to two brief consultations, currently under way: one relates to the list of terms themselves; the other, to technical considerations, such as: the forms to apply for the inclusion, alteration or removal of terms from the DCB-PS list, and labelling requirements. The proposals (published officially in the May 15 Di�rio Oficial da União) can be accessed via the Anvisa website (www.anvisa.gov.br); the consultations are scheduled to end on June 15.
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.